by Dennis Crouch Amgen v. Sanofi and Regeneron (Fed. Cir. 2021) The decision here provides another anti-functional-limitation decision — this time rendering Amgen’s monoclonal antibody claims invalid.  Although enablement decisions traditionally differed greatly between biotech and computer innovations, the decision here relies heavily on the Federal Circuit’s recent software decision in McRO, Inc. v. Bandai Namco Games … Continue reading Functional Claim “Raises the Bar for Enablement”